Related Experiment Video
Updated: Mar 13, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
13.5K
Impact of clinical pharmacy interventions on medication error nodes.
Nibal R Chamoun1,2, Rony Zeenny2, Hanine Mansour3,4
1Lebanese American University School of Pharmacy, Byblos, Lebanon.
International Journal of Clinical Pharmacy
|October 23, 2016
Summary
Pharmacists significantly reduced medication-related problems (MRPs) by analyzing interventions across medication error nodes. This study highlights the impact of structured pharmacy interventions in improving patient safety and care quality.
Area of Science:
- Clinical Pharmacy
- Patient Safety
- Medication Error Analysis
Background:
- Pharmacist involvement enhances patient care quality and reduces medication errors.
- A consistent process for documenting pharmacy interventions is crucial but lacking.
- The American College of Clinical Pharmacy (ACCP) recommends a structured approach to pharmaceutical care plans.
Purpose of the Study:
- To analyze pharmacy interventions by grouping them according to medication-related problems (MRPs) and medication error (ME) nodes.
- To demonstrate the impact of pharmacy interventions in reducing MRPs.
- To report interventions based on ME nodes within cardiology and infectious disease services.
Main Methods:
- Retrospective analysis of 1174 documented pharmacy interventions.
- Grouping interventions by MRPs and five ME nodes (prescribing, administering, monitoring, documenting, dispensing).
- Development of a new pharmacy reporting sheet to link interventions with MRPs.
Main Results:
- 1091 interventions were classified as MRPs, with 340 MRPs per 1000 patient days.
- A 72% reduction in MRPs was observed across all ME nodes.
- High intervention acceptance rates were noted, particularly in prescribing (68.30%), monitoring (77.7%), and documenting errors (79.36%).
Conclusions:
- Pharmacy interventions, when analyzed by corresponding MRP and ME nodes, effectively demonstrate the pharmacist's role in reducing preventable MRPs.
- Structured analysis of interventions supports improved patient safety and medication therapy outcomes.
- The study underscores the importance of consistent documentation and analysis of pharmacy interventions.
Related Concept Videos
01:26Pharmaceutical Poisoning: Potential Scenarios
53
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
53
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
519
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
519
01:25Pharmacokinetics: Drug–Drug Interactions
600
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
600
01:19Pharmacovigilance
1.9K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
1.9K
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
57
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
57